Abstracts tagged "Scleroderma"

Abstract Number: 1822 • ACR Convergence 2024
Analysis of Differential Activation of Lysophosphatidic Acid Regulated Genes in Diffuse and Limited Cutaneous Systemic Sclerosis
Medha Kanitkar¹, Philip Yee², Stefano Rodolfi¹, Kristina Clark³, Voon Ong⁴ and Christopher Denton⁵, ¹University College London, London, United Kingdom, ²UCL, London, United Kingdom, ³University of Oxford, Oxford, United Kingdom, ⁴University College London, London, England, United Kingdom, ⁵University College London, Northwood, United Kingdom
Background/Purpose: Lysophosphatidic Acid (LPA) is a lipid mediator implicated in the pathogenesis of SSc and idiopathic pulmonary fibrosis. Phase 2 clinical trials targeting this biological…
Abstract Number: 2441 • ACR Convergence 2024
Investigating Kidney Disease Risks in Systemic Sclerosis (SSc) – Effects of Proton Pump Inhibitors (PPI): Retrospective Analysis
Irakli Tskhakaia and Arthur Lau, Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: Systemic Sclerosis (SSc) patients often experience gastrointestinal complications, frequently managed with proton pump inhibitors (PPIs). Despite evidence of PPI-related chronic kidney disease (CKD) risk in…
Abstract Number: 2684 • ACR Convergence 2024
Assessment of Skin in Patients with Systemic Sclerosis Using High Frequency Ultrasound : A Comparative Study with Histology and Clinical Parameters of Skin Disease
Ruhani Desai¹, Filemon Tan², Minghua Wu³, Jefferey Browning⁴, Samuel Theodore³, Meng Zhang³, Brian Skaug³, Maureen Mayes³ and Shervin Assassi³, ¹UTHealth Houston Division of Rheumatology, DeLand, FL, ²University of Texas at Houston McGovern Medical School, Houston, TX, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴Boston Univeristy, Boston, MA
Background/Purpose: The extent of skin involvement and its rate of progression can provide prognostic information for systemic sclerosis (SSc)-related morbidity and mortality. Moreover, skin assessment…
Abstract Number: 0692 • ACR Convergence 2024
Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³, Laura Sierra Herranz⁴, Javier Juan Garcia⁴, Ivan Castellvi Barranco⁵ and elvira Diez álvarez⁴, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, Leon, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Background/Purpose: Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc) and is one of the leading causes of morbidity and mortality. Recently,…
Abstract Number: 0957 • ACR Convergence 2024
Increased Collagen Deposition and Altered Immune Cell Profiles Are Present in Early and Late Stage Systemic Sclerosis with Gastrointestinal Involvement
Laura Much¹, Elena Pachera², Andrea Laimbacher¹, Henriette Didriksen³, Lars Aabakken⁴, Knut Ea Lundin⁴, Lumeng Li¹, Astrid Hofman¹, Pietro Bearzi⁵, Sophie Wagner⁶, Michael Scharl⁷, Øyvind Molberg⁸, Håvard Fretheim⁹, Oliver Distler¹⁰ and Anna-Maria Hoffmann-Vold⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Oslo University Hospital, Moss, Norway, ⁴Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁶University of Zurich, Schlieren, Switzerland, ⁷Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁹Oslo University Hospital, Oslo, Norway, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Gastrointestinal tract (GIT) involvement is highly prevalent among patients with systemic sclerosis (SSc) and is associated with high morbidity and mortality. However, treatment options…
Abstract Number: 1571 • ACR Convergence 2024
Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis
Vishal Kakkar¹, Sunhwa Kim², Yingtao Bi³, Christopher Wasson¹, Stefano Di Donato⁴, Rebecca Ross⁵, Marco Di Battista⁶, Enrico De Lorenzis⁷, Thierry Sornasse² and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²AbbVie, South San Francisco, CA, ³Abbvie, Worcester, MA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ⁵Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Pisa, United Kingdom, ⁷Catholic University of the Sacred Heart, Roma, Rome, Italy
Background/Purpose: In systemic sclerosis (SSc), interstitial lung disease (ILD) remains the leading cause of mortality. A decline in forced vital capacity (FVC) is considered a…
Abstract Number: 1824 • ACR Convergence 2024
Skin Macrophage Subtypes and Impact of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis: Results from Single-cell Analyses of an Observational Data Set and a Phase I/II Randomized Controlled Trial
Juliette Ferrant¹, Alain Lescoat², Valérie Lecureur³, Marie Lelong³, John Varga⁴, Robert Lafyatis⁵, Johann Gudjonsson⁴ and Dinesh Khanna⁴, ¹CHU Rennes, Rennes, France, ²CHU Rennes - University Rennes 1, Rennes, France, ³Rennes University, Rennes, France, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Macrophages play a major role in dcSSc-related skin fibrosis, with a mixed M1-M2 activation profile relying on the activation of JAK/STAT. Tofacitinib, a pan-JAK…
Abstract Number: 2444 • ACR Convergence 2024
Performance of the DETECT Algorithm and Cluster Analysis in Screening for Systemic Sclerosis Pulmonary Hypertension Groups
Ryan Osgueritchian¹, Hoda Mombeini¹, Vivek Jani², Adrianne Woods³, Steven Hsu¹, Matthew Lammi⁴, Paul Hassoun⁴, Fredrick Wigley⁵, Laura Hummers⁶, Stephen Mathai⁷, Ami Shah⁸ and Monica Mukherjee¹, ¹Johns Hopkins University Division of Cardiology, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University Division of Rheumatology, Baltimore, MD, ⁴Johns Hopkins University Division of Pulmonary and Critical Care Medicine, Baltimore, MD, ⁵Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁶Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁷Johns Hopkins University Division of Pulmonary and Critical Care Medicine,, Blatimore, ⁸Division of Rheumatology, Johns Hopkins University, Ellicott City, MD
Background/Purpose: Pulmonary hypertension (PH) portends poor outcomes in Systemic Sclerosis (SSc). Recent efforts for early identification and intervention in SSc patients with pulmonary arterial hypertension…
Abstract Number: 2688 • ACR Convergence 2024
HLA-DRB4: A Novel Susceptibility Locus in Systemic Sclerosis Patients with Severe Calcinosis
Sara Faghihi-Kashani¹, srijana davluri², Kamini Kuchinad³, Zuoming deng⁴, Faiza Naz⁴, Stefania Dell'Orso⁴, Zsuzsanna McMahan⁵, Laura Hummers⁶, Daniel Kastner⁷, Fredrick Wigley³, david fiorentino⁸, Christian Lood⁹, Ami Shah¹⁰, Lorinda Chung¹¹ and Pravitt Gourh⁴, ¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, Sunnyvale, CA, ³Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁵UTHealth Houston Division of Rheumatology, Houston, TX, ⁶Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁷National Human Genome Research Institute, Bethesda, MD, Bethesda, MD, ⁸Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ⁹Division of Rheumatology, University of Washington, Seattle, WA, Seattle, WA, ¹⁰Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ¹¹Stanford University, Woodside, CA
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease. Class II HLA alleles have been reported to play an important role in SSc pathogenesis. Calcinosis, deposition of…
Abstract Number: 0693 • ACR Convergence 2024
Behind the Bronchiectasis in Systemic Sclerosis. Prevalence and Risk Factors
Miriam Retuerto Guerrero¹, Clara Moriano², Paula Perez Garcia³, cristiana sieiro santos⁴ and elvira Diez álvarez³, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain
Background/Purpose: Bronchiectasis (BC) has been observed in association with Systemic Sclerosis (SSc). Esophageal dysmotility, immunosuppressive drugs and the direct effect of collagen deposition in the…
Abstract Number: 0960 • ACR Convergence 2024
The Esophageal Epithelium in Systemic Sclerosis: Cellular and Molecular Dysregulation Revealed by Single-Cell RNA Sequencing
Matthew Dapas¹, Margarette Clevenger¹, Hadijat Makinde², Tyler Therron¹, Dustin Carlson¹, Mary Carns³, Kathleen Aren³, Carrie Richardson², Cenfu Wei², Lutfiyya Muhammad⁴, John Pandolfino¹, Harris Perlman², Deborah Winter⁵ and Marie-Pier Tetreault¹, ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL, ³Northwestern University Division of Rheumatology, Chicago, IL, ⁴Northwestern Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Skokie, IL
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by vasculopathy and progressive fibrosis of the skin and internal organs. Individuals with SSc often…
Abstract Number: 1572 • ACR Convergence 2024
Associations Between the Gut Microbiota, Ultra-Processed Food Intake, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis
Ju Young Lee¹, Swapna Joshi², Arissa Young³, Jen Labus², Zsuzsanna McMahan⁴, Ezinne Aja², Jonathan Jacobs² and Elizabeth Volkmann⁵, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA, Los Angeles, CA, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles
Background/Purpose: Alterations in the gastrointestinal (GI) microbiome (i.e., dysbiosis) are a feature of systemic sclerosis (SSc) [1]. Diet is a known modifier of the GI…
Abstract Number: 1825 • ACR Convergence 2024
Proteomic and Transcriptomic Analysis Reveal Elevated Senescent Signature in Systemic Sclerosis Fibrosis
Poulami Dey, Hiroshi Kato, Suiyuan Huang, Johann Gudjonsson, Dinesh Khanna, John Varga and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is marked by persistent fibrosis affecting both the skin and internal organs. Some regard SSc as a manifestation of expedited aging,…
Abstract Number: 2450 • ACR Convergence 2024
Disease Progression in Anti-Centromere Positive Systemic Sclerosis Patients
Eva Hoekstra¹, S. Ahmed², David Ueckert³, Nina Ajmone Marsan³, Philippine Kiès³, M.K. Ninaber³, Marlies Heuvers³, Miranda Geelhoed³, Thomas Huizinga⁴ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Leids Universitair Medisch Centrum, Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: Disease progression in systemic sclerosis (SSc) is characterized by severe and early progression in anti-topoisomerase (ATA) positive diffuse cutaneous patients and typically involves lung…
Abstract Number: PP08 • ACR Convergence 2024
Whispers of Resilience: Navigating Life with Rheumatism
Vinchelle Hardison and Vinchelle Hardison, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: “What’s wrong with me mom? Why am I always slow and hurting? Why can’t I play without being in pain like the other kids?”…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].